With Release of Aperture, Proscia Brings Clinical Labs Closer to Drug Discovery

In yet another sign that diagnostic data offers clinical laboratories potential new revenue streams, pathology AI company Proscia today announced the release of Aperture, a precision medicine tool.

From an anatomic pathology perspective, the most interesting aspect is that the new product gives labs a greater role in the drug discovery process.

Aperture identifies potential clinical trial or precision medicine candidates, tapping into a global laboratory network expected to deliver more than 8 million pathology diagnoses this year through Proscia’s Concentriq platform, the company noted in a press release. Its AI sifts through tissue images along with AI-derived biomarkers, molecular results, and clinical records to generate evidence for regulatory submissions and companion diagnostic development. 

Proscia said it safeguards protected health information through anonymizing clinical data.

New revenue streams attract clinical laboratory managers

For participating clinical labs at academic medical centers, healthcare systems, and reference laboratory companies, Aperture can turn pathology from a diagnostic function to a strategic revenue driver, according to Proscia. 

"For example, laboratories using Aperture can play a bigger role in patient recruitment since its AI identifies trial and study candidates at the point of diagnosis," Nathan Buchbinder, Proscia’s chief strategy officer, told Today's Clinical Lab. "The same AI also surfaces data cohorts, helping laboratories to increasingly capitalize on their deidentified data to advance specific biopharma needs such as biomarker studies or companion diagnostic development."

Generally, given the difficulties that clinical labs face in terms of staffing shortages, shrinking Medicare reimbursement, and tighter operating environments, lab managers may find themselves looking to other revenue streams that don’t involve introducing a new test panel.

Kyle Dunn, CEO and founder at healthcare sales intelligence firm Hyperdrive Bio, noted during a session at the 2025 Executive War College conference that lab data is ripe for use by third parties. 

“Pathology labs have the data,” Dunn said. “They have biospecimens, clinical expertise, and relationships with local care communities.”

Drug discovery companies are also increasingly eyeing medical labs as collaborators as therapies evolve. For example, as demand grows for treatments to battle neurodegenerative diseases, it will increase the need for medical lab testing to detect signs of these illnesses.

Citing statistics from a 2025 article in the journal JCO Clinical Cancer Informatics, Proscia stated that fewer than one in 10 cancer patients enroll in clinical trials, and others miss life-saving therapies altogether.